KAYEXALATE

Google image searchProduct monograph

Active ingredient

sodium polystyrene sulfonate, 1 G/G

DIN: 02026961

Dosage form(s): POWDER FOR SUSPENSION

Route(s) of administration: ORAL, RECTAL

Schedule: Prescription

Company: SANOFI-AVENTIS CANADA INC

Date: 06-FEB-2009

ATC:

• V03 — ALL OTHER THERAPEUTIC PRODUCTS (ATC, ATC/DDD, )
• V03A — ALL OTHER THERAPEUTIC PRODUCTS (ATC, ATC/DDD)
• V03AE — Drugs for treatment of hyperkalemia and hyperphosphatemia (ATC, ATC/DDD)
• V03AE01 — POLYSTYRENE SULPHONATE (ATC/DDD)

Reference brand drug: Kayexalate

Pharmaceutical standard: USP

External Links for Kayexalate

Search on Google

• Kayexalate side effects
• Kayexalate dosage
• sodium polystyrene sulfonate side effects
• sodium polystyrene sulfonate dosage

Sanofi-Aventis Canada Inc

Go to Sanofi-Aventis website to see drug product details. Sometimes you can find kayexalate photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.